Our data support the potential of DNA repair scores to identify CN-AML patients whose malignant cells are dependent on specific DNA repair pathways to design targeted therapy with ATM, CHEK-1/2, RAD51, or CDK7 inhibitors exploiting the addiction to deregulated DNA repair mechanisms. The gene discussed is RAD51; the disease is acute myeloid leukemia.